SCHEDULE: Sands Capital Discloses Significant SpyGlass Pharma Stake

Sands Capital entities and Frank M. Sands have reported significant beneficial ownership in SpyGlass Pharma, Inc., with Frank M. Sands holding 7.8% of common stock.

Summary

• Reporting Persons include Sands Capital Life Sciences Pulse Fund III (DE), L.P., Sands Capital Life Sciences Pulse Fund III-Holdings, L.P., Sands Capital Alternatives, LLC, and Frank M. Sands.
• The issuer is SpyGlass Pharma, Inc., with its principal executive offices located at 27081 ALISO CREEK ROAD, SUITE 125, ALISO VIEJO, CALIFORNIA, 92656.
• Total shares outstanding for SpyGlass Pharma, Inc. were 31,911,164 as of February 6, 2026, based on the Issuer's 424B4 Prospectus.
• Frank M. Sands beneficially owns 2,500,012 shares of common stock, representing 7.8% of the class, with shared voting and dispositive power.
• Sands Capital Life Sciences Pulse Fund III-Holdings, L.P. beneficially owns 2,079,215 shares, representing 6.5% of the class, with shared voting and dispositive power.
• Sands Capital Life Sciences Pulse Fund III (DE), L.P. beneficially owns 420,797 shares, representing 1.3% of the class, with shared voting and dispositive power.
• Sands Capital Alternatives, LLC beneficially owns 420,797 shares, representing 1.3% of the class, with shared voting and dispositive power.
• The Reporting Persons certify that the securities were not acquired and are not held for the purpose of changing or influencing the control of SpyGlass Pharma, Inc.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as it signals significant institutional investor confidence in SpyGlass Pharma, Inc. through a substantial beneficial ownership stake by Sands Capital and its affiliates.

Positives

• Sands Capital, a notable investment firm specializing in life sciences, and Frank M. Sands have reported significant beneficial ownership in SpyGlass Pharma, Inc., indicating institutional confidence in the company.
• Frank M. Sands, who holds ultimate voting and investment power over the Sands Funds, now beneficially owns 7.8% of SpyGlass Pharma's common stock.

Negatives

• No specific negative points are directly discernible from this Schedule 13G filing, which primarily reports beneficial ownership.

Risks

• The reporting persons certify that the securities were not acquired and are not held for the purpose of changing or influencing the control of the issuer, indicating a passive investment approach that will not actively push for corporate changes.

Future Outlook

This filing does not contain forward-looking statements or guidance from SpyGlass Pharma, Inc. It solely reports beneficial ownership by an institutional investor.

Management Comments

• "The securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."

Industry Context

StockSavvy.ai notes that the disclosure of a significant passive stake by a specialized life sciences fund like Sands Capital Life Sciences Pulse Fund III, and its affiliates, suggests a long-term investment perspective in SpyGlass Pharma, Inc. This type of institutional backing is common in the biotech and pharmaceutical sectors, where companies often require substantial capital and patient investors for R&D and commercialization efforts.

Comparison to Industry Standards

• This filing is a standard disclosure of beneficial ownership by an institutional investor, which is a common occurrence across all industries. It does not provide specific performance metrics for comparison to industry benchmarks or competitors.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake by Sands Capital may increase investor confidence and potentially attract further institutional interest.
• Management: The presence of a substantial, passive institutional investor like Sands Capital may provide a degree of stability and long-term focus, without immediate pressure for control changes.

Next Steps

• No specific future actions or milestones for SpyGlass Pharma, Inc. are mentioned in this beneficial ownership report.

Key Dates

Recommendation

The filing indicates a significant beneficial ownership stake by Sands Capital and Frank M. Sands, a reputable institutional investor. While this signals confidence, a Schedule 13G is a passive filing and does not provide operational or financial performance data to warrant a 'buy' or 'sell' recommendation. The substantial institutional interest suggests a 'hold' position for existing investors, while new investors should conduct further due diligence on the company's fundamentals.

Keywords

SpyGlass Pharma, Sands Capital, institutional ownership, beneficial ownership, Schedule 13G, common stock, investment, life sciences